The first three authors contributed equally to this work The last two authors share credit in this work for senior authorship Inflammatory bowel diseases (IBD) describe a group of complex intestinal disorders characterized by inflammation in the gastrointestinal tract. Current treatments for IBD include the use of antiinflammatory drugs; furthermore, recombinant lactic acid bacteria have been used as a therapeutic vehicle for anti-inflammatory agents in IBD models. Interleukin-lO (IL-IO) is one of the most important anti-inflammatory cytokines; however, its oral administration is limited because it is quickly degraded in the gastrointestinal tract and systemic treatments have led to undesirable side effects. In this study, an engineered invasive strain of Lactococcus (L.) lactis producing Fibronectin Binding Protein A (FnBPA+), from Staphylococcus aureus capable of delivering, directly inside eukaryotic cells, an eukaryotic DNA expression vector containing the ORF coding for IL-IO of Mus musculus (pValac:il-IO) was developed and its functionality was evaluated using in vitro and in vivo assays. Functionality of the plasmid and the invasive strain was demonstrated by transfection and invasiveness assays using cell cultures and in vivo in mice by fluorescence microscopy. TNBS inoculated mice that received this novel strain showed lower damage scores in their large intestines (at both macroscopic and microscopic levels), lower microbial translocation to liver, and increased anti-inflammatory/pro-inflammatory cytokine ratios compared to mice that received L. lactis FnBPA+ without the pValac:il-IO plasmid. The effectiveness was demonstrated of this novel DNA delivery therapeutic strategy in the prevention of inflammation using a murine model of colitis.
Inflammatory bowel diseases (IBD) describe a group ofcomplex intestinal disorders characterized by inflammation in the gastrointestinal tract (GIT) and are manifested in two main forms, ulcerative colitis (UC) and Crohn's disease (CD). Despite extensive research in recent years, the exact aetiology and pathogenesis of these disorders remain unclear (I).
Current treatments for IBD are restricted to surgery and the use of anti-inflammatory drugs, immunosuppressants and antibiotics. These drugs have shown moderate therapeutic effect; however, they can cause serious side effects which have revealed the need of a better therapeutic approach (I).
Interleukin-l0 (IL-I0) is one of the most important anti-inflammatory cytokines involved in the intestinal immune system (2) , and is known for its capacity of down-regulating inflammatory cascades through the suppression of pro-inflammatory cytokines (3) and therefore presents itself as a good therapeutic candidate for the treatment of IBD. The role oflL-lO as an essential immune-regulator in the intestinal tract has been demonstrated using IL-I0-deficient mice (4) . These animals develop a chronic bowel inflammation resembling CD in humans. However, systemic treatment with IL-lOis quite limited because it causes discomfort and undesirable secondary effects. In this sense, it was reported that when IL-I0 was systemically administrated at a high dose (20 ug/kg), there was an increase in the production ofIFN-y by peripheral blood lymphocytes; furthermore, this treatment was not clinically efficient in patients with active CD (5) . Oral treatment with IL-I0 is also limited because of its extreme sensitivity to the environment of the GIT. Taken together, the correct administration and delivery (i.e. formulation) is of critical importance for the development of an efficient therapy for the treatment of IBD.
Lactic acid bacteria (LAB) have shown to be effective mucosal delivery vehicles for the heterologous proteins of vaccinal, medical, or technological interest (6, 7) . The first evidence of the potential of recombinant Lactococcus (L.) lactis as a therapeutic vehicle was published in 2000, when it was shown that an L. lactis strain secreting IL-IO prevented the onset of colitis in IL-l 0-/-mice (8) , and reduced the inflammation in DSS-induced chronic colitis (9) . An important step forward towards the safe use of genetically modified (GM)-LAB for human therapeutic purposes was the construction of a biological containment system for human ILl O-producing L. lactis (10).This containment system was evaluated in CD patients and no adverse effects were produced after consuming this GM-LAB (II). Nevertheless, the clinical results did not reveal a statistically significant difference in mucosal healing versus placebo. However, since this strain must produce IL-I0 and release it, its clinical use is still hindered by the sensitivity of the cytokine in the GIT, reasons for which novel means of administration for more effective mucosal delivery of therapeutic LAB are currently being developed (12, 13) .
In this regard, DNA delivery at mucosal level allowing a molecule of interest to be expressed by eukaryotic host cells is a promising strategy (14, 15) . In this order a new plasmid vector for DNA delivery using lactococci, called pValac (Vaccination using lactic acid bacteria), was developed (16) . Both L. lactis MG 1363expressing either Staphylococcus aureus Fibronectin-Binding Protein A (FnBPA) or Listeria monocytogenes internalin A (InIA) were able to efficiently internalize and deliver the pValac plasmid in human epithelial cells and trigger DNA expression by these eukaryotic cells(l7).This effect can be related to the presence of FnBPA or InlA that acted likean adhesin and/or an invasin facilitating its adherence and/or internalisation into the host cells(l8). More recently it was demonstrated in mice that L. lactis (FnBPA+) strain was more efficient to deliver DNA than L. lactis Wt (l9).The objective of this study was to provide a new strategy for the prevention or treatment of IBD using the invasive genetically modified L. lactis MG 1363 FnBPA+ strain to deliver a therapeutic plasmid to host cells for in situ expression ofIL-lO. This strategy could provide a more efficient administration of IL-l 0 in the GIT which would not only be cheaper to produce than conventional anti-inflammatory therapy drugs but also more directed to the site of inflammation.
MATERIALS AND METHODS

Bacterial strains, growth conditions and plasmids
The bacterial strains and plasmids used in this work are listed in Table I . Escherichia (E.) coli TG1 was aerobically grown in Luria-Bertani (LB) medium at 37°C with vigorous shaking. 1. lactis MG1363 FnBPA+ was grown in M17 (Difco, Sparks, MD,USA) medium supplemented with 0.5% glucose (GM17) at 30°C without shaking. Bacteria were selected by addition of antibiotics as following: for E. coli, 10 ug/ml, chloramphenicol (Cm); for 1. lactis, 10 ug/ml, chloramphenicol and/or 5 ug/ml, erythromycin (Ery). For animal trials, 16-h cultures of 1. lactis were washed twice with 5 mL ofsaline solution (0.15 M NaCl) in order to eliminate any remaining traces of the antibiotic, and resuspended in 1 mL of saline solution for animal feedings.
DNA manipulations
General DNA manipulation techniques were carried out according to standard procedures. Unless otherwise indicated, DNA restriction and modification enzymes were used as recommended by the suppliers. DNA fragments were isolated from agarose gels using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare Life Sciences, Chalfont St. Giles, UK). PCR amplifications were performed using Accu Prime Table I . Bacterial strains and plasmids used in this work.
Pfx DNA Polymerase (Invitrogen) and/or GoTaq DNA Polymerase (Invitrogen, Carlsbad, CA, USA) in a DNA thermo cycler (MJ Research, Inc.). Plasmid DNA from E. coli and 1. lactis were isolated as previously described (20) with the following modifications: for plasmid DNA extraction from 1. lactis, the first step included addition ofTES (25% sucrose, 1 mM EDTA, 50 mM Tris-HCl, pH 8) containing lysozyme (10 mg/mL) for 30 min at 37°C to prepare protoplasts. Electroporation of E. coli and 1. lactis was performed as previously described (21) .E. coli transformants were plated onto LB agar plates containing the required antibiotic for 24h at 37°C, whereas 1. lactis transformants were plated onto GM17 agar plates containing the required antibiotic and were counted after 2-day incubation at 30°C.
p Valac:il-l 0 construction
A 537 bp DNA fragment, contammg the coding sequence of IL-IO from Mus musculus, was generated by PCR using the PJ201 plasmid (Table  I) 16 17 This work 17 Source DNA 2.0 (Merlo Park, CA, USA) 16 16 This work (Invitrogen) and the oligonucleotides IL-IOF (5'-ACCATGGCTGGCTCAGCACTGCTATGC-3') and IL-IOR (5'-GATATCTTAGCTTTTCATTTTGATCATCAT-3 '), containing the artificial restriction sites (BamHI and EcoRV) at each end (underlined) and the customized Kozak sequence (bold). The amplified product and the pValac vector (Table 1) were both digested with BamHI and EcoRV, gel purified, ligated using the T4 DNA ligase (Promega, Madison, WI, USA) and transformed in E. coli TG I (Table I ) to obtain the desired construction, pValac:il-10. The integrity of the insert was confirmed by PCR and sequencing (data not shown).
Transfection assays and analysis of1L-10 production and secretion by eukaryotic cells using confocal microscopy, flow cytometry and ELiSA
The pValac:il-10 plasmid was assayed for IL-lO expression by transfection into the Chinese Hamster Ovary (CHO) cell line. CHO cells were cultured in complete Nutrient Mixture FI2 Ham medium (Sigma, St Louis, USA), supplemented with 10% foetal bovine serum (Gibco), 1% L-glutamine (Sigma, St Louis, USA), zeocine (100 ng/mL) and 2.5% hepes (Sigma, St Louis, USA), until 80-90% confluence was obtained. CHO cells were transfected with 4 ug of pValac:il-10 or pValac (empty vector), previously complexed with Lipofectamine2000 (Invitrogen), or were incubated without any plasmid (negative control). After 48 hof transfection, the IL-IOproducing cells, as well as the control cells, were washed twice with Phosphate Buffered Saline (PBS) solution, immediately fixed with parafonnaldehyde 2% for 15 min and penneabilized with Triton X-lOO 0.1% for 10 min at room temperature. The cells were then incubated with the rat monoclonal anti-mouse IL-I 0 primary antibody (Santa Cruz Biotechnology, Santa Cruz, California, USA) in PBS for 2 h at room temperature, followed by incubation with rabbit polyclonal anti-rat Alexa Fluor 488 (Invitrogen) in PBS and with DAPI (4,6'-diamidino-2-phenylindole -Invitrogen), for cell nucleus staining, for I h. Samples were mounted with hydramount and the images were captured using an LSM 510 Meta Zeiss inverted confocal laser-scanning microscope equipped with an argon laser and blue filter with maximum emission of 520 nm; a filter with emission around 461 nm was used for DAPI detection. Images of each sample were collected and analyzed using Zeiss LSM Image Browser software.
For flow cytometry analysis, the CHO cells that were transfected with the pValac:il-lO plasmid, were fixed and penneabilized using the Foxp3 Staining Buffer Set (eBioscience, San Diego, California, USA). After washing with PBS, the cells were incubated with the rat monoclonal anti-mouse IL-IO (Santa Cruz Biotechnology, Santa Cruz, California, USA) for 30 min at room temperature followed by 30 min incubation at room temperature with rabbit polyclonal anti-rat Alexa Fluor 488 (Invitrogen, Carlsbad, CA, USA). The cell samples were washed, centrifuged and resupended in PBS. Quantification of IL-10 producing CHO cells was performed using FACScan (Becton Dickinson Bioscience) equipment and data acquired were analyzed using the FlowJo 7.6.4 (TreeStar, Ashland, OR, USA) program. Cells transfected with pValac:gfp plasmid were analyzed as positive control.
The concentration of secreted IL-IO in the culture medium by CHO cells transfected with the pValac:il-10 or pValac plasmid was determined after 48 h oftransfection using the BD OptEIA cytokine ELISA set (BD Bioscience, San Diego, Calif., USA), according to the manufacturer's indications. Non-transfected CHO cells were used as control. The supernatant was first passed through a 30 KDaAmicon Ultra-Centrifugal Filter Device and centrifuged for lOmin (concentration factor 22x); the recovery was then passed through a 10 KDa device and centrifuged for l Omin (concentration factor 12x), and the final concentrate was then used for ELISA determination,
Invasiveness assays of1. lactis strains in Caco-2 human epithelial cells.
The co-culture assays were performed with the human colon carcinoma cell line Caco-2 (ATCC HTB37), as described previously (17) . Briefly, these cells were cultured in RPMI-1640 AQmedia (Sigma, St Louis, USA) supplemented with 10% foetal bovine serum (FBS). Under these experimental conditions, Caco-2 cells from passages 85 to 87 were used and maintained without antibiotics. The number of cells tested was 4 x 10 5 per dish using 6 well plates. 1. lactis strains were grown to an optical density of 0.9 to 1.0 at 600 nm, washed and diluted in PBS so that the multiplicity of infection was about 10 3 bacteria per cell, giving about 4 x 10 8 per dish. Caco-2 epithelial cells were co-incubated with (i) 1. lactis MG1363 FnBPA+ (Wt), (ii) 1. lactis MG1363 FnBPA+ containing pValac:gfp or (iii) 1. lactis MGl363 FnBPA+ containing pValac:il-lO. After 3 h of co-culture, gentamicin (20 mg/L) was added to kill non-internalized lactococci and the mixture was incubated for an additional 2 h in complete RPMI medium. Cells were collected 24, 48 and 72 h after gentamicin treatment; using trypsin-EDTA solution for 8 min. Enzyme activity was stopped by the addition of culture medium containing FBS. After washing with PBS, the cells were incubated with the rabbit monoclonal anti-mouse IL-lO antibody (ProSci Inc" Poway CA, USA) for 30 min at room temperature followed by 30 min incubation at room temperature with FITC goat polyclonal anti-rabbit antibody (Jackson Immuno Research, Labs. Inc. West Grove, USA). The cell samples were washed, centrifuged and resupended in PBS. Quantification of IL-IO and OFP-producing cells was performed using FACS Calibur flow cytometer (Becton Dickinson) equipment, and data acquired were analyzed using the FCS Express program (Becton Dickinson).
Green fluorescent protein (GFP) detection in enterocytes from the large intestines ofmice
In order to evaluate whether the pValac vector could be released and used by colon epithelial cells to produce proteins, six BALB/c mice were fed by gavage with 10 8 UFC/mouse of L. lactis MGl363 FnBPA+ containing pValac:gjp or 1. lactis MGl363 FnBPA+ without the expression vector. Twenty-four and 48h post-administration, three mice per group and three mice without bacteria supplementation were sacrificed and large intestines were removed, washed with PBS and prepared for histological evaluation using standard techniques. Serial paraffin sections (4 11m) were made and after deparaffination, slides were prepared for direct observation at 160, 400 and 1000X using a fluorescence light microscope.
Induction of intestinal inflammation and feeding procedure in mice
Five-week-old female BALB/c mice weighing 20-25 g were obtained from the inbred closed colony maintained at CERELA (Centro de Referencia para Lactobacilos, San Miguel de Tucuman, Argentina). Intestinal inflammation was induced using a previously described technique (22) . Briefly, mice were anesthetized intraperitoneally using a mixture of ketamine hydrocholoride (Holliday-Scott S.A., Buenos Aires, Argentina; 100 ug/g body weight), and xylazine hydrochloride (Rompun, BAYER, Division Sanidad Animal, Buenos Aires, Argentina; 5 ug/g body weight) after which they received an intrarectal (i.r.) administration of 100 III of a solution of Trinitrobenzenesulfonic acid (TNBS, Sigma, St. Louis; 2 mg/mouse) dissolved in phosphate buffered saline (PBS) solution 0.01 M, pH 7.4 mixed with an equal volume of ethanol (50% ethanol). Control mice (Mock group) received PBS mixed with ethanol (without TNBS) using the same technique.
One day before TNBS inoculation, mice were subdivided into 4 experimental groups: i) mock group where mice received an i.r. administration of 50% ethanol instead of TNBS and no special feeding; ii) inflammation group (TNBS group) where mice were inoculated with TNBS and they did not receive special feeding; iii) Wt group, where TNBS inoculated mice received the 1. lactis MGl363 FnBPA+ (Wt strain); iv) pValac:il-IO group, where TNBS inoculated mice received 1. lactis MO1363 FnBPA+ containing pValac:il-IO.
Mice that received bacterial supplementation did so by intragastric gavage of 100111 bacterial suspension (containing 2 xl O? CFU/mL) in PBS once daily, starting one day before TNBS inoculation until the end of the experiment (3 days post-TNBS). Mice from mock and TNBS group received daily the same volume of PBS.
All animals also received a balanced diet ad libitum and were maintained in a room with a l2-h light/dark cycle at l8±2°C. Each experimental group consisted of 6 mice. Body weight and animal mortality rates were controlled on a daily basis.
All animal protocols were preapproved by the Animal Protection Committee of CERELA (CRL-BIOT-LT-20l0/lA) and all experiments comply with the current laws of Argentina.
Macroscopic and histological evaluation of intestinal inflammation
Three days after TNBS inoculation, three mice per group were sacrificed. Large intestines and caecum were removed, visually inspected for macroscopic evaluation, and prepared for histological evaluation using standard methods. Serial paraffin sections of 4 11m were made and stained with hematoxilin-eosin for light microscopy examination. Macroscopic lesions were assessed using a previously described scoring system (22) .Each parameter (erythema, hemorrhage, oedema, stricture formation, ulceration, fecal blood, presence of mucus, diarrhea and adhesions) was awarded 1 point if observed in tissue examination. The extent of colonic damage and inflammation was assessed using a standard histopathological grading system as previously described (23): histological findings identical to normal mice (grade 0); mild mucosal and/or submucosal inflammatory infiltrate (admixture of neutrophils) and oedema, punctate mucosal erosions often associated with capillary proliferation, Muscularis mucosae intact (grade 1); grade 1 changes involving 50% of the specimen (grade 2); prominent inflammatory infiltrate and oedema (neutrophils usually predominating) frequently with deeper areas of ulceration extending through the muscularis mucosae into the submucosa; rare inflammatory cells invading the muscularis propria but without muscle necrosis (grade 3); grade 3 changes involving 50% of the specimen (grade 4);extensive ulceration with coagulative necrosis bordered inferiorly by numerous neutrophils and lesser numbers of mononuclear cells; necrosis extends deeply into the muscularis propria (grade 5); grade 5 changes involving 50% of the specimen (grade 6).
The analyses were performed by two different researchers. High macroscopic or histological scores indicate increased damage in the intestines.
Determination ofcytokines in intestinal tissues andfluids
Cytokine positive ceIls were detected by indirect immunofluorescence on large intestine tissue slides, foIlowing a previously described technique (24) . Briefly, after deparaffination, rabbit anti-mouse IL-IO (ProSci Inc., Poway CA, USA) or goat anti-mouse IL-17 (BD Bioscience, San Diego, USA) polyclonal antibodies (diluted in saponin-PBS) were applied to the 4 urn sections for 75 min at room temperature. The sections were then incubated with a dilution of goat anti-rabbit or rabbit antigoat antibody conjugated with fluorescein isothiocyanate (FITC; Jackson Immuno Research Laboratories Inc., West Grove, USA). The number of fluorescent cells was counted by two different researchers (two individual blind counts per sample) and the results were expressed as the mean number of positive ceIls in ten fields of vision as seen at 1000X using a fluorescence light microscope.
Intestinal contents were coIlected from the large intestines of mice with ImL PBS and immediately centrifuged at 5000gfor 15 min at 4°C. The supernatants were recovered, a complete mini EDTA-free protease inhibitor cocktail was added (Roche Molecular Biochemicals, Indianapolis, IN, USA) and stored at -20°C until determinations. These samples were used with the BD Cytometric Bead Array (CBA) Mouse Thl/Th2/Th17 Cytokine Kit that can be used to measure IL-2, IL-4, IL-6, IFN-y, TNF, IL-17A, and IL-IO protein levels in a single sample, foIlowing the manufacturer's instructions. Cytokine quantification was performed using a FACS Calibur flow cytometer (Becton Dickinson) equipment, and data acquired for each sample and standard (provided by the manufacture) were analyzed using the software FCAP Array V1.0.1 (Becton Dickinson).
The concentration of each cytokine from the intestinal fluid of each mouse was obtained and the results were also expressed as cytokine ratios for each mouse to show the cytokine balance in the animals and not only the individual cytokine concentrations in the intestinal fluid which can be affected by the intestinal transit during the inflammatory process.
Statistical analysis
For animal trials, the test and control groups contained 6 animals, and three mice for each group were sacrificed in each sample taken. The experimental protocol was performed three times (no interactions between these three trials were observed) and all the results (from the three trials) were analyzed together (N=9).Statistical analyses were performed using MINITAB 15 software. A factorial experimental design (replicates -treatment) was used for the experiments. Comparisons were accomplished by an ANOVA general linear model foIlowed by a Tukey's post hoc test and p < 0.0 I was considered significant.
The in vitro analyses were performed three times and the results were analyzed together (N=3).
RESULTS
Construction of 1. lactis MG1363 FnBPA+ p Valac:il-l 0
The pValac:il-lO plasmid harbours an eukaryotic region containing the Cyto Megalo Virus promoter (pCMV), the open reading frame (ORF) of Mus musculusIL-IO and the polyadenylation signal of Bovine growth hormone (BGR polyA), required for gene expression by eukaryotic host cells, as well as a prokaryotic region containing the RepA / RepC replication origins for both E. coli and 1. lactis and a chloramphenicol resistance gene (Cm) for bacteria selection (Fig. la) . The construction of the pValac:il-l 0 plasmid was confirmed by PCR and sequencing (data not shown). The pValac:il-lO plasmid was inserted into 1. lactis MG 1363 FnBPA+ (hereby referred to as the Wt strain), a recombinant strain that is capable of adhering and invading eukaryotic cells, resulting in the recombinant 1. lactis MG1363 FnBPA+ pValac:il-lO strain.
Functionality of the pValac:il-lO plasmid in eukaryotic cells in vitro.
In order to determine expression and secretion of murine IL-IO by eukaryotic cells and subsequently the functionality of pValac:il-lO, this plasmid was transfected in CRO cells. Using confocal microscopy it was possible to observe, 48 h after transfection, that pValac:il-lO transfected CRO cells were able to produce IL-IO ( Fig. 1d) , while non-transfected CRO cells (Fig. 1b) , and cells transfected with the pValac (empty vector, Fig. Ic) , did not. Flow cytornetry experiment confirmed that 88% of CRO cells transfected with pValac:il-l 0 plasmid produced IL-IO ( Fig.1g ), compared to 2.6% ofnon-transfected cells (Fig. 1f ). After being concentrated, IL-IO was detected by enzyme-linked immunosorbent assay (ELISA) at values of55± 10 pg/mL, whereas secretion of this cytokine was not detectable in the cells transfected with the control plasmid (pValac:gfj:J) or without plasmid (data not shown), confirming the functionality of the pValac:il-l 0 plasmid. The plasmid pValac:gfj:J was used as positive control in these assays and by flow cytometry it was observed that more than 95% of CHO cells transfected with this vector were positive (Fig. 1e ). L. lactis MG 1363 FnBPA+ was also shown to be effective in delivering pValac:il-l 0 in eukaryotic cells. When L. lactis MGl363 FnBPA+ pValac:il-10 was co-incubated with Caco-2 cells, 2.07% of this human cell line effectively produced IL-IO (as observed by flow cytometry) one day after removing the bacterium, and this number of IL-I O-producing cells remained constant for at least 3 days post coincubation (data not shown).
Oral administration of L. lactis MG1363 FnBPA+ pl/alac.gfp showed protein expression in large intestine cells L. lactis MGl363 FnBPA+ pValac:gfjJ was orally administered to mice. In each individual experiment, fluorescent cells were only observed in mice that received L. lactis MG 1363 FnBPA+ pValac:gfjJ, whereas no fluorescent epithelial cells were observed in animals that received the same strain without the expression vector (L. lactis MG 1363 FnBPA+, Fig. 2 ).
Therapeutic effect oforal administration ofL. lactis MG1363 FnBPA+ pValac:il-lO against TNBSinduced colitis
The administration of L. lactis MG1363 FnBPA+ pValac:il-l 0 to mice was able to decrease the severity ofthe colitis induced by TNBS. Mice that received L. lactis MG1363 FnBPA+ pValac:il-10 (pValac:il-IO group) showed decrease body weight loss compared to those that received L. lactis MG 1363 FnBPA+ (Wt group) or mice without any treatment (TNBS group, Fig. 3a) .
Macroscopic observations of the large intestines showed a significant decrease in the score of inflammation in mice from pValac:il-l 0 group compared to mice from the TNBS and Wt groups (Fig.  3b ). Mock control mice showed a mean histological score of 0.5±0.2 (Fig. 3b and 3d ). The induction of the inflammation with TNBS increased the score in the TNBS group Microbial translocation to the liver was also evaluated because intestinal damage can cause the spread of many microorganisms from the intestinal lumen to distant organs. In all evaluated growth media, mice that receivedL.lactis MG 1363 FnBPA+ pValac:il-l 0 showed a significant decrease in the liver microbial counts compared to those TNBSinoculated that received the Wt strain or no bacterial supplementation (Fig. 3c) .
The analysis of cytokine-producing cells was performed in the large intestine tissues and showed that mice with elevated histological damage (TNBS and Wt groups) increased significantly The analysis of cytokines secreted to the intestinal lumen showed that IL-IO concentrations increased in all the TNBS-inoculated mice (Fig. 5e) ; however, IL-17 and IFN-y increased significantly (P<O.OI) in the fluid of mice from TNBS group, compared to mice from pValac:il-l 0 group (Fig.  5f-h) . The concentration of TNF in the intestinal fluids did not vary between the animals from each test group (Fig. 5g ). The results led to demonstrate significant differences in the anti-inflammatory/proinflammatory cytokine ratios in the intestinal lumen between the mice from TNBS and Wt group, and the mice from pValac:il-lO group (Fig. 5i) . The other cytokines analyzed in the array were not detected in the intestinal fluid by the kit used.
DISCUSSION
Many groups have been trying to develop new anti-inflammatory therapies for the treatment ofIBD using IL-IO as the active ingredient, and different strategies have been designed to deliver IL-IO directly to the GIT. One such system is the use of a nanoparticles-in-microsphere oral system (25); however, it would be very expensive and complicated to scale-up to an industrial level. Another alternative is the use of LAB to deliver beneficial compounds (15, 26, 27) .
Recombinant IL-IO producing L. lactis strains were developed as a therapeutic delivery system (8) , and it effectiveness was reported using animal models (9, 22) and also in CD patients (phase 1 clinical trial) (10, 11) . Unfortunately a phase 2 clinical trial did not show any differences between patients treated with placebo or GM-LAB.
In all of the above-mentioned studies involving the use of engineered LAB, IL-IO was produced by the bacterial cells that directly delivered it to the GIT. In the present study, a new therapeutic approach for the treatment of lED using L. lactis expressing FnBPA that has the capacity to efficiently internalize and trigger recombinant DNA expression by human epithelial cells (17, 19) was evaluated.
For this purpose, a new plasmid called pValac:il-l 0 was constructed (Fig. la) . Its functionality was confirmed by transfecting CRG cells with pValac:il-lO which were then able to produce and secrete murine IL-IO (Figs. l d and l g). The pValac:il-lO plasmid was then inserted into the genetically engineered strain of L. lactis MG 1363 FnBPA+ and this new construction, L. lactisMG 1363 FnBPA+ pValac:il-lO was analyzed in vivo.
In order to evaluate the delivery of the pValac plasmid by L. lactis MG1363 FnBPA+ and its functionality in vivo, healthy animals were given the recombinant L. lactis MG1363 FnBPA+ pValac:gflJ strain. GFP was expressed in the epithelial cells of the large intestine ( Fig. 2 ) and as it was previously shown that oral administration of this same strain produced GFP+ epithelial cells in the small intestines (19) , we can confirm that oral administration of L. lactis MG1363 FnBPA+ pValac was able to trigger recombinant protein expression in eukaryotic host cells in both large and small intestines; however, we cannot discard the possibility that other cells besides epithelial cells, such as dendritic cells (DC), might also be a target for our delivery system.
The therapeutic effect of L. lactis MG 1363 FnBPA+ pValac:il-lOwas evaluated in an acute TNBS-induced colitis model in mice. This model was selected because it shares important similarities with human CD (28) (29) (30) .It was observed that mice given L. lactis MG1363 FnBPA+ pValac:il-lO had decreased severity of the inflammation with low macroscopic and microscopic inflammatory scores in the large intestine, decrease of microbial translocation to liver, and less body weight loss (Fig.  3) . Changes in the intestinal cytokine profile were also analyzed ( Figs. 4 and 5) .
IL-17 was evaluated because it has been found to be elevated in a variety of inflammatory conditions including lED (30) . The decrease of IL-17+ cells in our model in animals that received L. lactis MG 1363 FnBPA+p Valac:il-l 0, compared to mice that received the Wt strain or no bacterial supplementation (TNBS group), confirmed its anti-inflammatory effect, ( Fig.  4e and 4f ).
IL-IO producer cells were also analyzed to evaluate whether the administration of L. lactis MG1363 FnBPA+ pValac:il-lO could influence the normal body response against an inflammatory agent. Previous works have demonstrated that TNBSinoculated mice showed an increase in the number of IL-IO+ cells in the lamina propia of the large intestine, as a normal immune response against the inflammatory process; however, the IL-IO increases were not sufficient to prevent the increases of proinflammatory cytokines that remained elevated. In the present study, the number of IL-IO+ cells increased similarly in the intestinal tissues ofTNBS, Wt and pValac:il-lO groups compared to the mock control even though the number of IL-17+ cells was significantly decreased in the animals given L. lactis MG1363 FnBPA+ pValac:il-lO ( Figs. 4e and 4f) .
The anti-inflammatory profile observed in the intestinal tissue was also demonstrated when the cytokines secreted to the intestinal fluid were analyzed. Mice that received L. lactis MG 1363 FnBPA+ pValac:il-lO showed decreased levels of pro-inflammatory cytokines (IL-17 and IFNyamma) and maintained IL-IO concentration similar (or even increased in some animals) to the other mice inoculated with TNBS. Moreover, IL-10 levels increased in mice fed with the newly constructed strain (compared to the mock group) showing an anti-inflammatory effect by increased production of the anti-inflammatory cytokine IL-10 ( Fig. 5) .This contrast to previous experiments, where IL-IO+ cells and IL-IO levels remained low and the pro-inflammatory cytokines decreased when an anti-inflammatory strain was administered (22, 23, 31) . Here, a constant production of IL-l 0 due to the insertion of the pValac:il-l 0 plasmid in the host cells would prevent the inflammation by continuous production of IL-l 0, whereas in IL-IOproducing strains, a transient increase was observed (22) . Considering the epithelial turnover in the mouse intestine (estimated in 1.5 days and may be enhanced during inflammation), the constant production of IL-l 0 by these cells could be induced by the daily administration of the strain. This sustained production of IL-l 0 caused an increased in the IL-IO/pro-inflammatory cytokine ratios in the large intestine that were observed in both the intestinal tissues ( Fig. 4f ) and fluids ( Fig. 4f and  5i ). This anti-inflammatory profile confirms the important protection observed in mice that received the L. lactis MG1363 FnBPA+ pValac:il-10, where damage scores and production of pro-inflammatory cytokines were lower than those reported previously with other anti-inflammatory strains (22, 23) . The results of this trial in a representative illustration of the large intestine of mice given L. lactis MG 1363 FnBPA+ pValac:il-lO administration in a TNBS mouse model is shown in Fig. 6 .
These results show that L.lactis MG 1363 FnBPA+ pValac:il-l 0 is a good alternative to maintain an antiinflammatory status in the GIT, especially for chronic CD patients, demonstrating the effectiveness of this novel DNA delivery-based strategy. New studies using non-invasive strains and the study of which host cells are targeted are currently underway.
